Advertisement

HIV, Depression, and Cognitive Impairment in the Era of Effective Antiretroviral Therapy

  • Leah H. RubinEmail author
  • Pauline M. Maki
Central Nervous System and Cognition (SS Spudich, Section Editor)
  • 139 Downloads
Part of the following topical collections:
  1. Topical Collection on Central Nervous System and Cognition
  2. Topical Collection on Central Nervous System and Cognition

Abstract

Purpose of Review

Mental health disorders, especially depression, are prevalent among people living with HIV (PLWH) and are associated with cognitive impairment (CI) among HIV-uninfected (HIV−) individuals. We conducted a comprehensive review of the link between depression and cognition among PLWH.

Recent Findings

Studies examining depression and cognition in PLWH report high rates of current (median = 24%) and lifetime depression (42%). There is reliable evidence that depression is associated with overall CI among PLWH, and in the cognitive domains of processing speed, executive function, learning and memory, and motor function. Although few studies have examined the interaction between HIV serostatus and depression on CI, there is no evidence of a stronger association between CI and depression in PLWH compared with HIV− controls.

Summary

Depression is prevalent and reliably associated with CI in PLWH, with an overall pattern of domain-specific associations similar to that of HIV− individuals.

Keywords

HIV Depression Depressive symptoms Cognitive impairment HAND 

Notes

Acknowledgements

Research reported in this publication was supported by the National Institute of Mental Health of the National Institutes of Health under Award Number R01MH113512 (Rubin).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

  1. 1.
    Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Orlando M, Burnam MA, Beckman R, Morton SC, London AS, Bing EG, et al. Re-estimating the prevalence of psychiatric disorders in a nationally representative sample of persons receiving care for HIV: results from the HIV Cost and Services Utilization Study. Int J Methods Psychiatr Res. 2002;11(2):75–82.CrossRefPubMedGoogle Scholar
  4. 4.
    Cook JA, Burke-Miller JK, Steigman PJ, Schwartz RM, Hessol NA, Milam J, et al. Prevalence, comorbidity, and correlates of psychiatric and substance use disorders and associations with HIV risk behaviors in a multisite cohort of women living with HIV. AIDS Behav. 2018;22(10):3141–54.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Do AN, Rosenberg ES, Sullivan PS, Beer L, Strine TW, Schulden JD, et al. Excess burden of depression among HIV-infected persons receiving medical care in the United States: data from the medical monitoring project and the behavioral risk factor surveillance system. PLoS One. 2014;9(3):e92842.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sherr L, Cluver L. World Health Day focus on HIV and depression - a comorbidity with specific challenges. J Int AIDS Soc. 2017;20(1):21956.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Nanni MG, Caruso R, Mitchell AJ, Meggiolaro E, Grassi L. Depression in HIV infected patients: a review. Curr Psychiatry Rep. 2015;17(1):530.CrossRefPubMedGoogle Scholar
  8. 8.
    Grov C, Golub SA, Parsons JT, Brennan M, Karpiak SE. Loneliness and HIV-related stigma explain depression among older HIV-positive adults. AIDS Care. 2010;22(5):630–9.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Mascolini M. Depression risk factors with HIV -- plus screening and diagnosis keys. In: The Center for AIDS Information & Advocacy; 2016. http://www.thebodypro.com/content/77778/depression-risk-factors-with-hiv--plus-screening-a.html
  10. 10.
    Slot M, Sodemann M, Gabel C, Holmskov J, Laursen T, Rodkjaer L. Factors associated with risk of depression and relevant predictors of screening for depression in clinical practice: a cross-sectional study among HIV-infected individuals in Denmark. HIV medicine. 2015;16(7):393–402.CrossRefPubMedGoogle Scholar
  11. 11.
    Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum EE, Schuman P, Boland RJ, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA. 2001;285(11):1466–74.CrossRefPubMedGoogle Scholar
  12. 12.
    Thames AD, Arentoft A, Rivera-Mindt M, Hinkin CH. Functional disability in medication management and driving among individuals with HIV: a 1-year follow-up study. J Clin Exp Neuropsychol. 2013;35(1):49–58.CrossRefPubMedGoogle Scholar
  13. 13.
    Thames AD, Kim MS, Becker BW, Foley JM, Hines LJ, Singer EJ, et al. Medication and finance management among HIV-infected adults: the impact of age and cognition. J Clin Exp Neuropsychol. 2011;33(2):200–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Marquine MJ, Flores I, Kamat R, Johnson N, Umlauf A, Letendre S, et al. A composite of multisystem injury and neurocognitive impairment in HIV infection: association with everyday functioning. J Neuro-Oncol. 2018;24:549–56.Google Scholar
  15. 15.
    Thaler NS, Sayegh P, Arentoft A, Thames AD, Castellon SA, Hinkin CH. Increased neurocognitive intra-individual variability is associated with declines in medication adherence in HIV-infected adults. Neuropsychology. 2015;29(6):919–25.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Poquette AJ, Moore DJ, Gouaux B, Morgan EE, Grant I, Woods SP, et al. Prospective memory and antiretroviral medication non-adherence in HIV: an analysis of ongoing task delay length using the memory for intentions screening test. J Int Neuropsychol Soc : JINS. 2013;19(2):155–61.CrossRefPubMedGoogle Scholar
  17. 17.
    Woods SP, Weber E, Weisz BM, Twamley EW, Grant I, Group HIVNRP. Prospective memory deficits are associated with unemployment in persons living with HIV infection. Rehabil Psychol. 2011;56(1):77–84.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Scott JC, Woods SP, Vigil O, Heaton RK, Schweinsburg BC, Ellis RJ, et al. A neuropsychological investigation of multitasking in HIV infection: implications for everyday functioning. Neuropsychology. 2011;25(4):511–9.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Zogg JB, Woods SP, Weber E, Iudicello JE, Dawson MS, Grant I, et al. HIV-associated prospective memory impairment in the laboratory predicts failures on a semi-naturalistic measure of health care compliance. Clin Neuropsychol. 2010;24(6):945–62.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Gorman AA, Foley JM, Ettenhofer ML, Hinkin CH, van Gorp WG. Functional consequences of HIV-associated neuropsychological impairment. Neuropsychol Rev. 2009;19(2):186–203.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Doyle K, Weber E, Atkinson JH, Grant I, Woods SP, Group HIVNRP. Aging, prospective memory, and health-related quality of life in HIV infection. AIDS Behav. 2012;16(8):2309–18.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Tozzi V, Balestra P, Murri R, Galgani S, Bellagamba R, Narciso P, et al. Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. Int J STD AIDS. 2004;15(4):254–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Tozzi V, Balestra P, Galgani S, Murri R, Bellagamba R, Narciso P, et al. Neurocognitive performance and quality of life in patients with HIV infection. AIDS Res Hum Retrovir. 2003;19(8):643–52.CrossRefPubMedGoogle Scholar
  24. 24.
    Osowiecki DM, Cohen RA, Morrow KM, Paul RH, Carpenter CC, Flanigan T, et al. Neurocognitive and psychological contributions to quality of life in HIV-1-infected women. AIDS (London, England). 2000;14(10):1327–32.CrossRefGoogle Scholar
  25. 25.
    Uthman OA, Magidson JF, Safren SA, Nachega JB. Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis. Curr HIV/AIDS Rep. 2014;11(3):291–307.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Sin NL, DiMatteo MR. Depression treatment enhances adherence to antiretroviral therapy: a meta-analysis. Ann Behav Med. 2014;47(3):259–69.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquired Immune Deficiency Syndromes (1999). 2011;58(2):181–7.CrossRefGoogle Scholar
  28. 28.
    Lima VD, Geller J, Bangsberg DR, Patterson TL, Daniel M, Kerr T, et al. The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS (London, England). 2007;21(9):1175–83.CrossRefGoogle Scholar
  29. 29.
    Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44(10):2029–40.CrossRefPubMedGoogle Scholar
  30. 30.
    Rubin LH, Sundermann EE, Cook JA, Martin EM, Golub ET, Weber KM, et al. Investigation of menopausal stage and symptoms on cognition in human immunodeficiency virus-infected women. Menopause (New York, NY). 2014;21(9):997–1006.CrossRefGoogle Scholar
  31. 31.
    Rubin LH, Cook JA, Springer G, Weber KM, Cohen MH, Martin EM, et al. Perceived and post-traumatic stress are associated with decreased learning, memory, and fluency in HIV-infected women. AIDS (London, England). 2017;31(17):2393–1401.CrossRefGoogle Scholar
  32. 32.
    Fellows RP, Byrd DA, Morgello S. Effects of information processing speed on learning, memory, and executive functioning in people living with HIV/AIDS. J Clin Exp Neuropsychol. 2014;36(8):806–17.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Shimizu SM, Chow DC, Valcour V, Masaki K, Nakamoto B, Kallianpur KJ, et al. The impact of depressive symptoms on neuropsychological performance tests in HIV-infected individuals: a study of the Hawaii Aging with HIV Cohort. World journal of AIDS. 2011;1(4):139–45.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Braganca M, Palha A. Depression and neurocognitive performance in Portuguese patients infected with HIV. AIDS Behav. 2011;15(8):1879–87.CrossRefPubMedGoogle Scholar
  35. 35.
    Baxter LR Jr, Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE, et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry. 1989;46(3):243–50.CrossRefPubMedGoogle Scholar
  36. 36.
    Rogers MA, Kasai K, Koji M, Fukuda R, Iwanami A, Nakagome K, et al. Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence. Neurosci Res. 2004;50(1):1–11.CrossRefPubMedGoogle Scholar
  37. 37.
    Koenigs M, Grafman J. The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav Brain Res. 2009;201(2):239–43.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Siegle GJ, Thompson W, Carter CS, Steinhauer SR, Thase ME. Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unipolar depression: related and independent features. Biol Psychiatry. 2007;61(2):198–209.CrossRefPubMedGoogle Scholar
  39. 39.
    Thomas EJ, Elliott R. Brain imaging correlates of cognitive impairment in depression. Front Hum Neurosci. 2009;3:30.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Erickson K, Drevets W, Schulkin J. Glucocorticoid regulation of diverse cognitive functions in normal and pathological emotional states. Neurosci Biobehav Rev. 2003;27(3):233–46.CrossRefPubMedGoogle Scholar
  41. 41.
    Gold PW, Drevets WC, Charney DS. New insights into the role of cortisol and the glucocorticoid receptor in severe depression. Biol Psychiatry. 2002;52(5):381–5.CrossRefPubMedGoogle Scholar
  42. 42.
    Plessis SD, Vink M, Joska JA, Koutsilieri E, Stein DJ, Emsley R. HIV infection and the fronto-striatal system: a systematic review and meta-analysis of fMRI studies. AIDS (London, England). 2014;28(6):803–11.CrossRefGoogle Scholar
  43. 43.
    Del Guerra FB, Fonseca JL, Figueiredo VM, Ziff EB, Konkiewitz EC. Human immunodeficiency virus-associated depression: contributions of immuno-inflammatory, monoaminergic, neurodegenerative, and neurotrophic pathways. J Neuro-Oncol. 2013;19(4):314–27.Google Scholar
  44. 44.
    Hong S, Banks WA. Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications. Brain Behav Immun. 2015;45:1–12.CrossRefPubMedGoogle Scholar
  45. 45.
    Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732–41.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Blackstone K, Moore DJ, Heaton RK, Franklin DR Jr, Woods SP, Clifford DB, et al. Diagnosing symptomatic HIV-associated neurocognitive disorders: self-report versus performance-based assessment of everyday functioning. J Int Neuropsychol Soc : JINS. 2012;18(1):79–88.CrossRefPubMedGoogle Scholar
  47. 47.
    Wright E, Brew B, Arayawichanont A, Robertson K, Samintharapanya K, Kongsaengdao S, et al. Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region. Neurology. 2008;71(1):50–6.CrossRefPubMedGoogle Scholar
  48. 48.
    Becker JT, Kingsley L, Mullen J, Cohen B, Martin E, Miller EN, et al. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology. 2009;73(16):1292–9.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Haddow LJ, Laverick R, Daskalopoulou M, McDonnell J, Lampe FC, Gilson R, et al. Multicenter European prevalence study of neurocognitive impairment and associated factors in HIV positive patients. AIDS Behav. 2018;22(5):1573–83.CrossRefPubMedGoogle Scholar
  50. 50.
    Yusuf AJ, Hassan A, Mamman AI, Muktar HM, Suleiman AM, Baiyewu O. Prevalence of HIV-associated neurocognitive disorder (HAND) among patients attending a tertiary health facility in Northern Nigeria. J Int Assoc Providers of AIDS Care. 2017;16(1):48–55.CrossRefGoogle Scholar
  51. 51.
    Gascon MRP, Vidal JE, Mazzaro YM, Smid J, Marcusso RMN, Capitao CG, et al. Neuropsychological assessment of 412 HIV-infected individuals in Sao Paulo, Brazil. AIDS Patient Care STDs. 2018;32(1):1–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Bonnet F, Amieva H, Marquant F, Bernard C, Bruyand M, Dauchy FA, et al. Cognitive disorders in HIV-infected patients: are they HIV-related? AIDS (London, England). 2013;27(3):391–400.CrossRefGoogle Scholar
  53. 53.
    Starace F, Bartoli L, Aloisi MS, Antinori A, Narciso P, Ippolito G, et al. Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study. Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study. Acta Psychiatr Scand. 2002;106(1):20–6.CrossRefPubMedGoogle Scholar
  54. 54.
    Pinheiro CA, Souza LD, Motta JV, Kelbert EF, Souza MS, Martins CS, et al. Depression and diagnosis of neurocognitive impairment in HIV-positive patients. Brazil J Med Biol Res = Revista brasileira de pesquisas medicas e biologicas. 2016;49(10):e5344.Google Scholar
  55. 55.
    Judd A, Le Prevost M, Melvin D, Arenas-Pinto A, Parrott F, Winston A, et al. Cognitive function in young persons with and without perinatal HIV in the AALPHI cohort in England: role of non-HIV-related factors. Clin Infect Dis : an official publication of the Infectious Diseases Society of America. 2016;63(10):1380–7.CrossRefGoogle Scholar
  56. 56.
    Bloch M, Kamminga J, Jayewardene A, Bailey M, Carberry A, Vincent T, et al. A screening strategy for HIV-associated neurocognitive disorders that accurately identifies patients requiring neurological review. Clin Infectious Dis : an official publication of the Infectious Diseases Society of America. 2016;63(5):687–93.CrossRefGoogle Scholar
  57. 57.
    Tymchuk S, Gomez D, Koenig N, Gill MJ, Fujiwara E, Power C. Associations between depressive symptomatology and neurocognitive impairment in HIV/AIDS. Can J Psychiatr. 2018;63(5):329–36.CrossRefGoogle Scholar
  58. 58.
    Castellon SA, Hardy DJ, Hinkin CH, Satz P, Stenquist PK, van Gorp WG, et al. Components of depression in HIV-1 infection: their differential relationship to neurocognitive performance. J Clin Exp Neuropsychol. 2006;28(3):420–37.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Richardson JL, Nowicki M, Danley K, Martin EM, Cohen MH, Gonzalez R, et al. Neuropsychological functioning in a cohort of HIV- and hepatitis C virus-infected women. AIDS (London, England). 2005;19(15):1659–67.CrossRefGoogle Scholar
  60. 60.
    Akolo C, Royal W 3rd, Cherner M, Okwuasaba K, Eyzaguirre L, Adebiyi R, et al. Neurocognitive impairment associated with predominantly early stage HIV infection in Abuja, Nigeria. J Neuro-Oncol. 2014;20(4):380–7.Google Scholar
  61. 61.
    Kelly CM, van Oosterhout JJ, Ngwalo C, Stewart RC, Benjamin L, Robertson KR, et al. HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: a cross sectional study. PLoS One. 2014;9(6):e98962.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Schouten J, Su T, Wit FW, Kootstra NA, Caan MW, Geurtsen GJ, et al. Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy. AIDS (London, England). 2016;30(7):1027–38.CrossRefGoogle Scholar
  63. 63.
    Harrison JD, Dochney JA, Blazekovic S, Leone F, Metzger D, Frank I, et al. The nature and consequences of cognitive deficits among tobacco smokers with HIV: a comparison to tobacco smokers without HIV. J Neuro-Oncol. 2017;23(4):550–7.Google Scholar
  64. 64.
    Janssen MA, Meulenbroek O, Steens SC, Goraj B, Bosch M, Koopmans PP, et al. Cognitive functioning, wellbeing and brain correlates in HIV-1 infected patients on long-term combination antiretroviral therapy. AIDS (London, England). 2015;29(16):2139–48.CrossRefGoogle Scholar
  65. 65.
    Rosenthal LS, Skolasky RL, Moxley RT, Roosa HV, Selnes OA, Eschman A, et al. A novel computerized functional assessment for human immunodeficiency virus-associated neurocognitive disorder. J Neuro-Oncol. 2013;19(5):432–41.Google Scholar
  66. 66.
    Ammassari A, Antinori A, Aloisi MS, Trotta MP, Murri R, Bartoli L, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004;45(5):394–402.CrossRefPubMedGoogle Scholar
  67. 67.
    Bryant VE, Whitehead NE, Burrell LE 2nd, Dotson VM, Cook RL, Malloy P, et al. Depression and apathy among people living with HIV: implications for treatment of HIV associated neurocognitive disorders. AIDS Behav. 2015;19(8):1430–7.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Lawler K, Mosepele M, Ratcliffe S, Seloilwe E, Steele K, Nthobatsang R, et al. Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study. J Int AIDS Soc. 2010;13:15.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Cysique LA, Brew BJ. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neuro-Oncol. 2011;17(2):176–83.Google Scholar
  70. 70.
    Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS (London, England). 2010;24(9):1243–50.Google Scholar
  71. 71.
    Molsberry SA, Lecci F, Kingsley L, Junker B, Reynolds S, Goodkin K, et al. Mixed membership trajectory models of cognitive impairment in the multicenter AIDS cohort study. AIDS (London, England). 2015;29(6):713–21.CrossRefGoogle Scholar
  72. 72.
    Armstrong NM, Surkan PJ, Treisman GJ, Sacktor NC, Irwin MR, Teplin LA, et al. Association of long-term patterns of depressive symptoms and attention/executive function among older men with and without human immunodeficiency virus. J Neuro-Oncol. 2017;23(4):558–67.Google Scholar
  73. 73.
    Heaton RK, Franklin DR Jr, Deutsch R, Letendre S, Ellis RJ, Casaletto K, et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis : an official publication of the Infectious Diseases Society of America. 2015;60(3):473–80.CrossRefGoogle Scholar
  74. 74.
    Vo QT, Cox C, Li X, Jacobson LP, McKaig R, Sacktor N, et al. Neuropsychological test performance before and after HIV-1 seroconversion: the Multicenter AIDS Cohort Study. J Neuro-Oncol. 2013;19(1):24–31.Google Scholar
  75. 75.
    Grant I, Franklin DR Jr, Deutsch R, Woods SP, Vaida F, Ellis RJ, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014;82(23):2055–62.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Robinson-Papp J, Byrd D, Mindt MR, Oden NL, Simpson DM, Morgello S, et al. Motor function and human immunodeficiency virus-associated cognitive impairment in a highly active antiretroviral therapy-era cohort. Arch Neurol. 2008;65(8):1096–101.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Cysique LA, Deutsch R, Atkinson JH, Young C, Marcotte TD, Dawson L, et al. Incident major depression does not affect neuropsychological functioning in HIV-infected men. J Int Neuropsychol Soc : JINS. 2007;13(1):1–11.CrossRefPubMedGoogle Scholar
  78. 78.
    Gandhi NS, Moxley RT, Creighton J, Roosa HV, Skolasky RL, Selnes OA, et al. Comparison of scales to evaluate the progression of HIV-associated neurocognitive disorder. HIV Ther. 2010;4(3):371–9.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Gibbie T, Mijch A, Ellen S, Hoy J, Hutchison C, Wright E, et al. Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up. HIV medicine. 2006;7(2):112–21.CrossRefPubMedGoogle Scholar
  80. 80.
    Nakasujja N, Skolasky RL, Musisi S, Allebeck P, Robertson K, Ronald A, et al. Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BMC psychiatry. 2010;10:44.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Cysique LA, Dermody N, Carr A, Brew BJ, Teesson M. The role of depression chronicity and recurrence on neurocognitive dysfunctions in HIV-infected adults. J Neuro-Oncol. 2016;22(1):56–65.Google Scholar
  82. 82.
    Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–99.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33 quiz 34–57.Google Scholar
  84. 84.
    Turner BJ, Laine C, Cosler L, Hauck WW. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med. 2003;18(4):248–57.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Aljassem K, Raboud JM, Hart TA, Benoit A, Su D, Margolese SL, et al. Gender differences in severity and correlates of depression symptoms in people living with HIV in Ontario, Canada. J Int Assoc Providers of AIDS Care. 2016;15(1):23–35.CrossRefGoogle Scholar
  86. 86.
    Semple SJ, Patterson TL, Straits-Troster K, Atkinson JH, McCutchan JA, Grant I. Social and psychological characteristics of HIV-infected women and gay men. HIV Neurobehavioral Research Center (HNRC) Group. Women Health. 1996;24(2):17–41.CrossRefPubMedGoogle Scholar
  87. 87.
    Rabkin J, Rabkin R. [Depression and HIV]. Sidahora 1997:19–22.Google Scholar
  88. 88.
    Robertson K, Bayon C, Molina JM, McNamara P, Resch C, Munoz-Moreno JA, et al. Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada. AIDS Care. 2014;26(12):1555–61.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Sherr L, Clucas C, Harding R, Sibley E, Catalan J. HIV and depression--a systematic review of interventions. Psychol Health Med. 2011;16(5):493–527.CrossRefPubMedGoogle Scholar
  90. 90.
    Safren SA, O’Cleirigh C, Tan JY, Raminani SR, Reilly LC, Otto MW, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009;28(1):1–10.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Safren SA, O’Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol. 2012;80(3):404–15.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Grelotti DJ, Hammer GP, Dilley JW, Karasic DH, Sorensen JL, Bangsberg DR, et al. Does substance use compromise depression treatment in persons with HIV? Findings from a randomized controlled trial. AIDS Care. 2017;29(3):273–9.CrossRefPubMedGoogle Scholar
  93. 93.
    Himelhoch S, Medoff D, Maxfield J, Dihmes S, Dixon L, Robinson C, et al. Telephone based cognitive behavioral therapy targeting major depression among urban dwelling, low income people living with HIV/AIDS: results of a randomized controlled trial. AIDS Behav. 2013;17(8):2756–64.CrossRefPubMedGoogle Scholar
  94. 94.
    Himelhoch S, Mohr D, Maxfield J, Clayton S, Weber E, Medoff D, et al. Feasibility of telephone-based cognitive behavioral therapy targeting major depression among urban dwelling African-American people with co-occurring HIV. Psychol Health Med. 2011;16(2):156–65.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Himelhoch S, Medoff DR. Efficacy of antidepressant medication among HIV-positive individuals with depression: a systematic review and meta-analysis. AIDS Patient Care STDs. 2005;19(12):813–22.CrossRefPubMedGoogle Scholar
  96. 96.
    Eshun-Wilson I, Siegfried N, Akena DH, Stein DJ, Obuku EA, Joska JA. Antidepressants for depression in adults with HIV infection. Cochrane Database Syst Rev. 2018;1:CD008525.PubMedGoogle Scholar
  97. 97.
    Ngo VK, Wagner GJ, Nakasujja N, Dickens A, Aunon F, Musisi S. Effectiveness of antidepressants and predictors of treatment response for depressed HIV patients in Uganda. Int J STD AIDS. 2015;26(14):998–1006.CrossRefPubMedGoogle Scholar
  98. 98.
    Mills JC, Harman JS, Cook RL, Marlow NM, Harle CA, Duncan RP, et al. Comparative effectiveness of dual vs. single-action antidepressants on HIV clinical outcomes in HIV-infected people with depression. AIDS (London, England). 2017;31(18):2515–24.CrossRefGoogle Scholar
  99. 99.
    Radtke KK, Bacchetti P, Anastos K, Merenstein D, Crystal H, Karim R, et al. Use of nonantiretroviral medications that may impact neurocognition: patterns and predictors in a large, long-term HIV cohort study. J Acquired Immune Deficiency Syndromes (1999). 2018;78(2):202–8.CrossRefGoogle Scholar
  100. 100.
    Rosenblat JD, Kakar R, RS MI. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. Int J Neuropsychopharmacol. 2015;19(2):pyv082.CrossRefPubMedPubMedCentralGoogle Scholar
  101. 101.
    Baune BT, Brignone M, Larsen KG. A network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. Int J Neuropsychopharmacol. 2018;21(2):97–107.CrossRefPubMedGoogle Scholar
  102. 102.
    Martin DM, McClintock SM, Forster JJ, Lo TY, Loo CK. Cognitive enhancing effects of rTMS administered to the prefrontal cortex in patients with depression: a systematic review and meta-analysis of individual task effects. Depress Anxiety. 2017;34(11):1029–39.CrossRefPubMedGoogle Scholar
  103. 103.
    McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol. 2016;19:pyw055.CrossRefPubMedCentralGoogle Scholar
  104. 104.
    Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010;167(7):748–51.CrossRefPubMedGoogle Scholar
  105. 105.
    Morris SE, Cuthbert BN. Research Domain Criteria: cognitive systems, neural circuits, and dimensions of behavior. Dialogues Clin Neurosci. 2012;14(1):29–37.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of NeurologyJohns Hopkins School of MedicineBaltimoreUSA
  2. 2.Department of EpidemiologyJohns Hopkins School of Public HealthBaltimoreUSA
  3. 3.Department of PsychiatryUniversity of Illinois at ChicagoChicagoUSA
  4. 4.Department of PsychologyUniversity of Illinois at ChicagoChicagoUSA

Personalised recommendations